1
|
Antuña Ramos A, Mayordomo-Colunga J, Blanco Lago R, Álvarez Vega MA. Decompressive craniectomy in the acute fulminant cerebral edema. NEUROCIRUGIA (ENGLISH EDITION) 2024:S2529-8496(24)00047-9. [PMID: 39074658 DOI: 10.1016/j.neucie.2024.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/02/2024] [Revised: 06/28/2024] [Accepted: 07/06/2024] [Indexed: 07/31/2024]
Abstract
Acute fulminant cerebral edema is a type of rapidly progressive encephalitis that occurs in children and is associated with significant morbidity and mortality. We present a clinical case with seizures, rapid neurological deterioration and the early appearance of cerebral herniation signs. Although the radiological tests were initially normal and there are no established parameters that predict the evolution of encephalitis to a rapidly progressive subtype, the clinical evolution forced to consider the decompressive craniectomy due to the lack of response to the medical management of the cerebral edema. It may be necessary take a brain biopsy to confirm the etiology of the encephalitis origin of acute fulminant cerebral edema. The objective of surgery should be not only to increase survival, but also to reduce subsequent neurological sequelae.
Collapse
Affiliation(s)
- Aida Antuña Ramos
- Departamento de Neurocirugía, Hospital Universitario Central de Asturias, Asturias, Spain
| | - Juan Mayordomo-Colunga
- Sección de Cuidados Intensivos Pediátricos, Hospital Universitario Central de Asturias, Asturias, Spain
| | - Raquel Blanco Lago
- AGC Pediatría, Neuropediatria, Hospital Universitario Central de Asturias, Asturias, Spain
| | | |
Collapse
|
2
|
MacRae CB, Grieco KC, Solomon IH. Diagnostic yield of postmortem brain examination following premortem brain biopsy for neoplastic and nonneoplastic disease. J Neuropathol Exp Neurol 2024; 83:331-337. [PMID: 38501995 PMCID: PMC11029448 DOI: 10.1093/jnen/nlae025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/20/2024] Open
Abstract
Medical autopsies have decreased in frequency due in part to advances in radiological techniques and increased availability of molecular and other ancillary testing. However, premortem diagnosis of CNS disease remains challenging; while ∼90% of brain tumor biopsies are diagnostic, only 20%-70% of biopsies for presumed nonneoplastic disease result in a specific diagnosis. The added benefits of performing an autopsy following surgical brain biopsy are not well defined. A retrospective analysis was performed of patients who underwent brain biopsy and autopsy at Brigham and Women's Hospital from 2003 to 2022. A total of 135 cases were identified, including 95 (70%) patients with primary CNS neoplasms, 16 (12%) with metastatic tumors, and 24 (18%) with nonneoplastic neurological disease. Diagnostic concordance between biopsy and autopsy diagnosis was excellent both for primary CNS neoplasms (98%) and metastatic tumors (94%). Conversely, patients with nonneoplastic disease received definitive premortem diagnoses in 7/24 (29%) cases. Five (21%) additional patients received conclusive diagnoses following autopsy; 8 (33%) received a more specific differential diagnosis compared to the biopsy. Overall, autopsy confirmed premortem diagnoses or provided new diagnostic information in 131/135 (97%) cases, highlighting the value in performing postmortem brain examination in patients with both neoplastic and nonneoplastic diseases.
Collapse
Affiliation(s)
- Cassie B MacRae
- Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Kristina C Grieco
- Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Isaac H Solomon
- Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
3
|
Piantadosi A, Shariatzadeh N, Bombin A, Arkun K, Alexandrescu S, Kleinschmidt-DeMasters BK, Solomon IH. Double-stranded RNA immunohistochemistry as a screening tool for viral encephalitis. Am J Clin Pathol 2023; 160:210-219. [PMID: 37141170 PMCID: PMC10392367 DOI: 10.1093/ajcp/aqad039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Accepted: 03/17/2023] [Indexed: 05/05/2023] Open
Abstract
OBJECTIVES Viral infections of the central nervous system can be challenging to diagnose because of the wide range of causative agents and nonspecific histologic features. We sought to determine whether detection of double-stranded RNA (dsRNA), produced during active RNA and DNA viral infections, could be used to select cases for metagenomic next-generation sequencing (mNGS) from formalin-fixed, paraffin-embedded brain tissue. METHODS Eight commercially available anti-dsRNA antibodies were optimized for immunohistochemistry (IHC) and the top antibody tested in a series of cases with confirmed viral infections (n = 34) and cases with inflammatory brain lesions of unclear etiology (n = 62). RESULTS Among known positives, anti-dsRNA IHC produced a strong cytoplasmic or nuclear staining pattern for Powassan virus, West Nile virus, rabies virus, JC polyoma virus, and adenovirus while failing to detect Eastern equine encephalitis virus, Jamestown Canyon virus, or any herpesvirus. All the unknown cases were negative by anti-dsRNA IHC, while mNGS detected rare viral reads (0.3-1.3 reads per million total reads) in 2 cases (3%), with only 1 having potential clinical significance. CONCLUSIONS Anti-dsRNA IHC can effectively identify a subset of clinically relevant viral infections but not all. The absence of staining should not exclude cases from mNGS if sufficient clinical and histologic suspicion exists.
Collapse
Affiliation(s)
- Anne Piantadosi
- Department of Pathology and Laboratory Medicine and Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, US
| | - Nima Shariatzadeh
- Department of Pathology and Laboratory Medicine and Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, US
| | - Andrei Bombin
- Department of Pathology and Laboratory Medicine and Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, US
| | - Knarik Arkun
- Department of Pathology and Laboratory Medicine, Tufts University School of Medicine, Boston, MA, US
| | - Sanda Alexandrescu
- Department of Pathology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, US
| | | | - Isaac H Solomon
- Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, US
| |
Collapse
|
4
|
Gupta N, Hiremath SB, Aviv RI, Wilson N. Childhood Cerebral Vasculitis : A Multidisciplinary Approach. Clin Neuroradiol 2023; 33:5-20. [PMID: 35750917 PMCID: PMC9244086 DOI: 10.1007/s00062-022-01185-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2022] [Accepted: 06/02/2022] [Indexed: 11/26/2022]
Abstract
Cerebral vasculitis is increasingly recognized as a common cause of pediatric arterial stroke. It can present with focal neurological deficits, psychiatric manifestations, seizures, and encephalopathy. The etiopathogenesis of childhood cerebral vasculitis (CCV) is multifactorial, making an inclusive classification challenging. In this review, we describe the common and uncommon CCV with a comprehensive discussion of etiopathogenesis, the role of various imaging modalities, and advanced techniques in diagnosing CCV. We also highlight the implications of relevant clinical, laboratory, and genetic findings to reach the final diagnosis. Based on the clinicoradiological findings, a stepwise diagnostic approach is proposed to facilitate CCV diagnosis and rule out potential mimics. Identification of key clinical manifestations, pertinent blood and cerebrospinal fluid results, and evaluation of central nervous system vessels for common and disease-specific findings will be emphasized. We discuss the role of magnetic resonance imaging, MR angiography, and vessel wall imaging as the imaging investigation of choice, and reservation of catheter angiography as a problem-solving tool. We emphasize the utility of brain and leptomeningeal biopsy for diagnosis and exclusion of imitators and masqueraders.
Collapse
Affiliation(s)
- Neetika Gupta
- Department of Medical Imaging, Children’s Hospital of Eastern Ontario (CHEO), University of Ottawa, Ottawa, Ontario Canada
- Clinical Fellow—Pediatric Radiology, Department of Medical Imaging, Children’s Hospital of Eastern Ontario (CHEO), University of Ottawa, Ottawa, Ontario Canada
| | - Shivaprakash B. Hiremath
- Department of Medical Imaging, Division of Neuroradiology, Civic and General Campus, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario Canada
- Joint Department of Medical Imaging, University of Toronto, Toronto, Ontario Canada
| | - Richard I. Aviv
- Department of Medical Imaging, Division of Neuroradiology, Civic and General Campus, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario Canada
| | - Nagwa Wilson
- Department of Medical Imaging, Children’s Hospital of Eastern Ontario (CHEO), University of Ottawa, Ottawa, Ontario Canada
| |
Collapse
|
5
|
Datyner E, Adeseye V, Porter K, Dryden I, Sarma A, Vu N, Patrick AE, Paueksakon P. Small vessel childhood primary angiitis of the central nervous system with positive anti-glial fibrillary acidic protein antibodies: a case report and review of literature. BMC Neurol 2023; 23:57. [PMID: 36737749 PMCID: PMC9895965 DOI: 10.1186/s12883-023-03093-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Accepted: 01/25/2023] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND Small vessel childhood primary angiitis of the central nervous system (SV-cPACNS) is a rare disease characterized by inflammation within small vessels such as arterioles or capillaries. CASE PRESENTATION We report a case of SV-cPACNS in an 8-year-old boy confirmed by brain biopsy. This patient was also incidentally found to have anti-glial fibrillary acidic protein (GFAP) antibodies in the cerebrospinal fluid (CSF) but had no evidence of antibody-mediated disease on brain biopsy. A literature review highlighted the rarity of SV-cPACNS and found no prior reports of CSF GFAP-associated SV-cPACNS in the pediatric age group. CONCLUSION We present the first case of biopsy proven SV-cPACNS vasculitis associated with an incidental finding of CSF GFAP antibodies. The GFAP antibodies are likely a clinically insignificant bystander in this case and possibly in other diseases with CNS inflammation. Further research is needed to determine the clinical significance of newer CSF autoantibodies such as anti-GFAP before they are used for medical decision-making in pediatrics.
Collapse
Affiliation(s)
- E Datyner
- grid.412807.80000 0004 1936 9916Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN USA
| | - V Adeseye
- grid.412807.80000 0004 1936 9916Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN USA
| | - K Porter
- grid.152326.10000 0001 2264 7217Vanderbilt University, Nashville, TN USA
| | - I Dryden
- grid.412807.80000 0004 1936 9916Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21St Avenue South, Nashville, TN MCN C2318B37232-2561 USA
| | - A Sarma
- grid.412807.80000 0004 1936 9916Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN USA
| | - N Vu
- grid.412807.80000 0004 1936 9916Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN USA
| | - AE Patrick
- grid.412807.80000 0004 1936 9916Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN USA
| | - P Paueksakon
- grid.412807.80000 0004 1936 9916Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21St Avenue South, Nashville, TN MCN C2318B37232-2561 USA
| |
Collapse
|
6
|
Al-Mansour LS, AlRasheed AA, AlEnezi KR, AlAli HM. Elevated intracranial pressure requiring decompressive craniectomy in a child with progressive primary angiitis of the central nervous system: a case report. J Med Case Rep 2021; 15:418. [PMID: 34353355 PMCID: PMC8344202 DOI: 10.1186/s13256-021-03005-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Accepted: 07/07/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Elevated intracranial pressure is a potentially catastrophic complication of neurologic injury in children. Successful management of elevated intracranial pressure requires prompt recognition and therapy directed at both reducing intracranial pressure and reversing its underlying cause. A rare condition that causes elevated intracranial pressure is childhood primary angiitis of the central nervous system, which is a rare inflammatory central nervous system disease that poses diagnostic and therapeutic challenges. To our knowledge, this is the first reported case of angiography-positive progressive childhood primary angiitis of the central nervous system requiring decompressive hemicraniectomy for refractory elevated intracranial pressure in children. CASE PRESENTATION We report the case of a 5-year-old Saudi girl who presented to the pediatric emergency department with fever and new-onset status epilepticus. She had elevated inflammatory markers with radiological and histopathological evidence of angiography-positive progressive childhood primary angiitis of the central nervous system, complicated by elevated intracranial pressure. Despite medical management for both childhood primary angiitis of the central nervous system and elevated intracranial pressure, her neurological status continued to deteriorate and the elevated intracranial pressure became refractory. She developed right uncal, right subfalcine, and tonsillar herniation requiring decompressive hemicraniectomy with a favorable neurological outcome. CONCLUSION Decompressive craniectomy might be considered in cases of angiography-positive progressive childhood primary angiitis of the central nervous system with elevated intracranial pressure refractory to medication. A multidisciplinary approach for the decision of decompressive craniectomy is advised to ensure patient safety and avoid possible morbidities and mortality.
Collapse
Affiliation(s)
- Lama S Al-Mansour
- Department of Pediatrics, Ministry of National Guards-Health Affairs, Riyadh, Saudi Arabia
- King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Abdulrahman A AlRasheed
- Department of Pediatrics, Ministry of National Guards-Health Affairs, Riyadh, Saudi Arabia
- King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Khaled R AlEnezi
- Department of Medical Imaging, Ministry of National Guards-Health Affairs, Riyadh, Saudi Arabia
- King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Hamza M AlAli
- Department of Pediatrics, Ministry of National Guards-Health Affairs, Riyadh, Saudi Arabia.
- King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
- College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
| |
Collapse
|
7
|
Layard Horsfall H, Toescu SM, Grover PJ, Hassell J, Sayer C, Hemingway C, Harding B, Jacques TS, Aquilina K. The utility of brain biopsy in pediatric cryptogenic neurological disease. J Neurosurg Pediatr 2020; 26:431-438. [PMID: 32619987 DOI: 10.3171/2020.4.peds19783] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2020] [Accepted: 04/20/2020] [Indexed: 11/06/2022]
Abstract
OBJECTIVE The authors' aim was to characterize a single-center experience of brain biopsy in pediatric cryptogenic neurological disease. METHODS The authors performed a retrospective review of consecutive brain biopsies at a tertiary pediatric neurosciences unit between 1997 and 2017. Children < 18 years undergoing biopsy for neurological pathology were included. Those with presumed neoplasms and biopsy performed in the context of epilepsy surgery were excluded. RESULTS Forty-nine biopsies in 47 patients (25 females, mean age ± SD 9.0 ± 5.3 years) were performed during the study period. The most common presenting symptoms were focal neurological deficit (28.6%) and focal seizure (26.5%). Histopathological, microbiological, and genetic analyses of biopsy material were contributory to the diagnosis in 34 cases (69.4%). Children presenting with focal seizures or with diffuse (> 3 lesions) brain involvement on MRI were more likely to yield a diagnosis at biopsy (OR 3.07 and 2.4, respectively). Twelve patients were immunocompromised and were more likely to yield a diagnosis at biopsy (OR 6.7). Surgery was accompanied by severe complications in 1 patient. The most common final diagnoses were infective (16/49, 32.7%), followed by chronic inflammatory processes (10/49, 20.4%) and occult neoplastic disease (9/49, 18.4%). In 38 cases (77.6%), biopsy was considered to have altered clinical management. CONCLUSIONS Brain biopsy for cryptogenic neurological disease in children was contributory to the diagnosis in 69.4% of cases and changed clinical management in 77.6%. Biopsy most commonly revealed underlying infective processes, chronic inflammatory changes, or occult neoplastic disease. Although generally safe, the risk of severe complications may be higher in immunocompromised and myelosuppressed children.
Collapse
Affiliation(s)
- Hugo Layard Horsfall
- Departments of1Neurosurgery
- 2Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital and University of Cambridge
| | - Sebastian M Toescu
- Departments of1Neurosurgery
- 3Developmental Imaging and Biophysics Section and
| | | | | | | | | | - Brian Harding
- 5Department of Pathology, Children's Hospital of Philadelphia, Pennsylvania
- 6Histopathology, Great Ormond Street Hospital for Children, London
| | - Thomas S Jacques
- 6Histopathology, Great Ormond Street Hospital for Children, London
- 7Developmental Biology and Cancer Department, UCL GOS Institute of Child Health, London, United Kingdom; and
| | | |
Collapse
|
8
|
Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, Klein-Gitelman MS, Benseler SM, Frankovich J, Gorman MP, Van Haren K, Dalmau J, Dale RC. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION 2020; 7:7/2/e663. [PMID: 31953309 PMCID: PMC7051207 DOI: 10.1212/nxi.0000000000000663] [Citation(s) in RCA: 157] [Impact Index Per Article: 39.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Accepted: 11/25/2019] [Indexed: 12/21/2022]
Abstract
Objective Autoimmune encephalitis (AE) is an important and treatable cause of acute encephalitis. Diagnosis of AE in a developing child is challenging because of overlap in clinical presentations with other diseases and complexity of normal behavior changes. Existing diagnostic criteria for adult AE require modification to be applied to children, who differ from adults in their clinical presentations, paraclinical findings, autoantibody profiles, treatment response, and long-term outcomes. Methods A subcommittee of the Autoimmune Encephalitis International Working Group collaborated through conference calls and email correspondence to consider the pediatric-specific approach to AE. The subcommittee reviewed the literature of relevant AE studies and sought additional input from other expert clinicians and researchers. Results Existing consensus criteria for adult AE were refined for use in children. Provisional pediatric AE classification criteria and an algorithm to facilitate early diagnosis are proposed. There is also discussion about how to distinguish pediatric AE from conditions within the differential diagnosis. Conclusions Diagnosing AE is based on the combination of a clinical history consistent with pediatric AE and supportive diagnostic testing, which includes but is not dependent on antibody testing. The proposed criteria and algorithm require validation in prospective pediatric cohorts.
Collapse
Affiliation(s)
- Tania Cellucci
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - Heather Van Mater
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - Francesc Graus
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - Eyal Muscal
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - William Gallentine
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - Marisa S Klein-Gitelman
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - Susanne M Benseler
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - Jennifer Frankovich
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - Mark P Gorman
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - Keith Van Haren
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - Josep Dalmau
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
| | - Russell C Dale
- From the Department of Pediatrics (T.C.), McMaster Children's Hospital, McMaster University, Hamilton, Ontario, Canada; Department of Pediatrics (H.V.M.), Duke University, Durham, NC; Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain; Department of Pediatrics (E.M.), Baylor College of Medicine, Houston, TX; Department of Neurology (W.G., K.V.H.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Division of Rheumatology (M.S.K.-G.), Ann & Robert H, Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL; Department of Pediatrics (S.M.B.), Alberta Children's Hospital, University of Calgary, Canada; Division of Pediatric Allergy, Immunology and Rheumatology (J.F.), Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard University, MA; Department of Neurology (J.D.), University of Pennsylvania, Philadelphia; Catalan Institution for Research and Advanced Studies (ICREA) (J.D.); Neuroimmunology Group (R.C.D.), Children's Hospital at Westmead, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.
| |
Collapse
|
9
|
Chiu M, Datta A. Childhood Small Vessel Primary Angiitis of the Central Nervous System: A Treatable Cause of Super-refractory Status Epilepticus. J Child Neurol 2020; 35:31-36. [PMID: 31530228 DOI: 10.1177/0883073819872579] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Childhood primary angiitis of the central nervous system (cPACNS) is a rare inflammatory disease of brain vessels. The small vessel subtype is diagnosed on brain biopsy and often presents with cognitive and behavioral changes, headaches, and seizures. However, there are few reported cases of super-refractory status epilepticus in children. We present a case of small vessel cPACNS complicated by super-refractory status epilepticus requiring burst suppression for 4 weeks in addition to multiple antiseizure medications and the ketogenic diet. Our patient was also treated with intravenous and oral steroids, intravenous immunoglobulin, and cyclophosphamide before starting maintenance therapy with mycophenolate mofetil. After prolonged rehabilitation, he recovered almost completely and has a normal neurologic examination with rare epileptiform activity on electroencephalogram (EEG). This is one of the longest cases of status epilepticus in small vessel cPACNS in the literature. We illustrate that super-refractory status epilepticus can be the first manifestation of small vessel cPACNS in previously healthy children and that symptomatic management of seizures with concurrent immunosuppression to treat the underlying pathology resulted in favorable neurologic outcomes.
Collapse
Affiliation(s)
- Michelle Chiu
- University of British Columbia and BC Children's Hospital, Division of Neurology, Department of Pediatrics, Vancouver, BC, Canada
| | - Anita Datta
- University of British Columbia and BC Children's Hospital, Division of Neurology, Department of Pediatrics, Vancouver, BC, Canada
| |
Collapse
|
10
|
Smitka M, Bruck N, Engellandt K, Hahn G, Knoefler R, von der Hagen M. Clinical Perspective on Primary Angiitis of the Central Nervous System in Childhood (cPACNS). Front Pediatr 2020; 8:281. [PMID: 32719754 PMCID: PMC7349935 DOI: 10.3389/fped.2020.00281] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Accepted: 05/04/2020] [Indexed: 12/21/2022] Open
Abstract
Non-arteriosclerotic arteriopathies have emerged as important underlying pathomechanism in pediatric arterial ischemic stroke (AIS). The pathogenesis and classification of cerebral arteriopathies in childhood are heterogeneous. Different classifications base on (i) the anatomic site; (ii) the distribution and size of the affected vessel; (iii) the time course, for example, transient vs. progressive, monophasic vs. recurrent; (iv) the putative pathogenesis; (v) the magnetic resonance imaging morphology of the vasculopathies. Inflammation affecting the cerebral vessels is increasingly recognized as common cause of pediatric AIS. Primary cerebral vasculitis or primary angiitis of the central nervous system (CNS) in childhood (cPACNS) is an important differential diagnosis in pediatric AIS. Primary angiitis of the CNS is a rare disorder, and the pathogenesis is poorly understood so far. The current classification of cPACNS is based on the affected cerebral vessel size, the disease course, and angiographic pattern. Two large subtypes are currently recognized comprising large- and medium-sized vessel CNS vasculitis referred to as angiography-positive cPACNS and angiography-negative small vessel cPACNS. As the clinical manifestations of cPACNS are rather diverse, precise diagnosis can be challenging for the treating pediatrician because of the lack of vital laboratory tests or imaging features. Initial misdiagnosis is common because of overlapping phenotypes and pediatric AIS mimics. As untreated cPACNS is associated with a high morbidity and mortality, timely diagnosis, and induction of immunomodulatory and symptomatic therapy are essential. Survival and neurological outcome depend on early diagnosis and prompt therapy. Primary angiitis of the central nervous system in childhood differs in several aspects from primary cerebral angiitis in adults. The aim of this article is to give a brief comprehensive summary on pediatric primary cerebral vasculitis focusing on the clinical perspective regarding the classification, the putative pathogenesis, the disease course, the diagnostic tools, and emerging treatment options. A modified terminology for clinical practice is discussed.
Collapse
Affiliation(s)
- Martin Smitka
- Abteilung Neuropädiatrie, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Normi Bruck
- Klinik für Kinder und Jugendmedizin, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Kay Engellandt
- Department of Neuroradiology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Gabriele Hahn
- Bereich Kinderradiologie, Medizinische Fakultät Carl Gustav Carus, Institut und Poliklinik für Radiologische Diagnostik, Technische Universität Dresden, Dresden, Germany
| | - Ralf Knoefler
- Klinik für Kinder und Jugendmedizin, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| | - Maja von der Hagen
- Abteilung Neuropädiatrie, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
| |
Collapse
|
11
|
Amlie-Lefond C. Evaluation and Acute Management of Ischemic Stroke in Infants and Children. Continuum (Minneap Minn) 2018; 24:150-170. [PMID: 29432241 DOI: 10.1212/con.0000000000000559] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE OF REVIEW This article provides an overview of stroke in neonates, infants, and children. RECENT FINDINGS Arterial ischemic stroke and cerebral venous sinus thrombosis are increasingly recognized in childhood as important causes of lifelong morbidity and mortality. Diagnosis of arterial ischemic stroke is frequently delayed, as acute neurologic deficits can be challenging to detect in the young child, and stroke is often not considered in the differential diagnosis. Neurologic sequelae following stroke are common, and strategies to minimize stroke size and optimize recovery are being developed. Recurrent arterial ischemic stroke is not uncommon, particularly in children with cerebral arteriopathy. Cerebral venous sinus thrombosis causes obstruction of venous outflow leading to venous infarcts. Complications include hemorrhagic conversion of infarcts and increased intracranial pressure. Without treatment, thrombus extension with increased symptoms is common. Robust guidelines of care that exist for adults do not exist for children, particularly for children with arterial ischemic stroke. SUMMARY The approach to stroke in infants and children can be informed by clinical experience in pediatric stroke and cerebral venous sinus thrombosis, the extensive literature on pediatric thrombosis, and extrapolation from data from adult patients.
Collapse
|
12
|
Limaye K, Samaniego EA, Adams HP. Diagnosis and Treatment of Primary Central Nervous System Angiitis. Curr Treat Options Neurol 2018; 20:38. [PMID: 30076478 DOI: 10.1007/s11940-018-0522-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE OF REVIEW Primary central nervous system angiitis (PCNSA) is a rare disease. Varying clinical pictures coupled with lack of sensitive and specific diagnostic tests lead to challenges in management of these patients. This unfortunately may lead to both under- or over-diagnosis and unnecessary treatment. It is important to recognize the different conditions that may mimic the clinical and radiologic presentation. We present a contemporary literature review that should update physicians who encounter this patient population. RECENT FINDINGS Recent additions to the literature in form of case reports and single-center series show that digital subtraction angiography was the most widely used test to diagnose PCNSA. It is also important to note that brain biopsy is still considered "gold standard" and should be pursued as it not only has information that establishes the diagnosis but also may help in ruling out the diagnosis from mimics. In around 39% of suspected cases, an alternate diagnosis was eventually confirmed highlighting the importance of a comprehensive work-up. For treatment, almost all the literature supports the use of glucocorticoids as the initial treatment and if the patient has a relapse or develops steroid toxicity then the second most commonly used agent was cyclophosphamide. There are increasing reports of benefits with other agents such as methotrexate, azathioprine, mycophenolate, infliximab, and etanercept. The diagnosis and management of PCNSA continues to be a challenge. Formation of prospective patient registries with continued immunologic research for novel targets and immunomodulatory modalities may hold promise for future care of these patients.
Collapse
Affiliation(s)
- Kaustubh Limaye
- Cerebrovascular Diseases, University of Iowa, Iowa City, IA, USA
| | - Edgar A Samaniego
- Neurology, Neurosurgery and Radiology, University of Iowa, Iowa City, IA, USA
| | | |
Collapse
|
13
|
Affiliation(s)
- Grace Kim
- From Partners Pediatric Multiple Sclerosis Center (G.K., T.C.), Massachusetts General Hospital; and Partners Multiple Sclerosis Center (T.C.), Brigham and Women's Hospital, Boston, MA.
| | - Tanuja Chitnis
- From Partners Pediatric Multiple Sclerosis Center (G.K., T.C.), Massachusetts General Hospital; and Partners Multiple Sclerosis Center (T.C.), Brigham and Women's Hospital, Boston, MA
| |
Collapse
|
14
|
Wilson N, Pohl D, Michaud J, Doja A, Miller E. MRI and clinicopathological correlation of childhood primary central nervous system angiitis. Clin Radiol 2016; 71:1160-7. [PMID: 27554617 DOI: 10.1016/j.crad.2016.07.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Revised: 05/30/2016] [Accepted: 07/18/2016] [Indexed: 11/28/2022]
Abstract
AIM To review the long-term clinical and imaging follow-up of eight children with histopathologically proven childhood primary central nervous system angiitis (cPACNS). MATERIALS AND METHODS Eight children (5-17 years, five female and three male patients) with biopsy-proven cPACNS vasculitis were reviewed retrospectively. All children were followed at the Children's Hospital of Eastern Ontario. Magnetic resonance imaging (MRI) images of the brain parenchyma and vessel pattern of the arteries of the circle of Willis were reviewed at baseline and follow-up(s). All MRI images were correlated with clinical and histopathological findings. RESULTS Seven (87.5%) children demonstrated parenchymal abnormalities: five of the seven (71.4%) presented with non-haemorrhagic lesions, one (14.3%) presented with a parenchymal bleed, and one (14.3%) showed diffuse oedema. One child remained negative for brain parenchymal abnormality at baseline and follow-up. Of the seven children with a parenchymal abnormality, parenchymal enhancement was seen in two (28.5%) and leptomeningeal enhancement was seen in one child. Only two children had positive diffusion-weighted imaging (DWI) restriction at baseline. Five of the seven children (71.4%) showed no magnetic resonance angiography (MRA) abnormalities at baseline. In one, MRA detected complete absence of flow. Follow-up MRA (24-74 months) demonstrated that five of the seven (71.4%) children had progressive paucity of the peripheral vascularity. Two children (28.5%) with shorter-term follow-up (7 and 13 months) did not demonstrate MRA changes. CONCLUSION Long-term follow-up MRA demonstrated progressive paucity of peripheral vessels, which could be secondary to the inflammation affecting the peripheral vasculature causing reduction in vessel lumen size beyond the resolution of the maximum intensity projection (MIP) reconstruction.
Collapse
Affiliation(s)
- N Wilson
- Diagnostic Imaging Department, Children's Hospital of Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1 Canada.
| | - D Pohl
- Diagnostic Imaging Department, Children's Hospital of Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1 Canada
| | - J Michaud
- Diagnostic Imaging Department, Children's Hospital of Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1 Canada
| | - A Doja
- Diagnostic Imaging Department, Children's Hospital of Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1 Canada
| | - E Miller
- Diagnostic Imaging Department, Children's Hospital of Eastern Ontario, 401 Smyth Rd, Ottawa, ON K1H 8L1 Canada
| |
Collapse
|
15
|
Britton PN, Eastwood K, Paterson B, Durrheim DN, Dale RC, Cheng AC, Kenedi C, Brew BJ, Burrow J, Nagree Y, Leman P, Smith DW, Read K, Booy R, Jones CA. Consensus guidelines for the investigation and management of encephalitis in adults and children in Australia and New Zealand. Intern Med J 2016; 45:563-76. [PMID: 25955462 DOI: 10.1111/imj.12749] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2014] [Accepted: 02/17/2015] [Indexed: 02/06/2023]
Abstract
Encephalitis is a complex neurological syndrome caused by inflammation of the brain parenchyma. The management of encephalitis is challenging because: the differential diagnosis of encephalopathy is broad; there is often rapid disease progression; it often requires intensive supportive management; and there are many aetiologic agents for which there is no definitive treatment. Patients with possible meningoencephalitis are often encountered in the emergency care environment where clinicians must consider differential diagnoses, perform appropriate investigations and initiate empiric antimicrobials. For patients who require admission to hospital and in whom encephalitis is likely, a staged approach to investigation and management is preferred with the potential involvement of multiple medical specialties. Key considerations in the investigation and management of patients with encephalitis addressed in this guideline include: Which first-line investigations should be performed?; Which aetiologies should be considered possible based on clinical features, risk factors and radiological features?; What tests should be arranged in order to diagnose the common causes of encephalitis?; When to consider empiric antimicrobials and immune modulatory therapies?; and What is the role of brain biopsy?
Collapse
Affiliation(s)
- P N Britton
- Discipline of Paediatrics and Child Health and Marie Bashir Institute for Emerging Infectious Diseases and Biosecurity, Sydney Medical School, University of Sydney, Sydney, Australia.,Department of Infectious Diseases and Microbiology, The Children's Hospital at Westmead, Sydney, Australia
| | - K Eastwood
- Health Protection, Hunter New England Population Health, Newcastle, New South Wales, Australia.,Biopreparedness, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
| | - B Paterson
- Biopreparedness, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
| | - D N Durrheim
- Biopreparedness, Hunter Medical Research Institute, Newcastle, New South Wales, Australia
| | - R C Dale
- Discipline of Paediatrics and Child Health and Marie Bashir Institute for Emerging Infectious Diseases and Biosecurity, Sydney Medical School, University of Sydney, Sydney, Australia.,Department of Neurology, The Children's Hospital at Westmead, Sydney, Australia
| | - A C Cheng
- Department of Infectious Diseases, The Alfred Hospital, Melbourne, Victoria, Australia.,Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
| | - C Kenedi
- Departments of, General Medicine, Auckland City Hospital, Auckland, New Zealand, USA.,Liaison Psychiatry, Auckland City Hospital, Auckland, New Zealand, USA.,Department of Medicine and Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA
| | - B J Brew
- St Vincent's Centre for applied medical research, University of New South Wales, Sydney, Australia.,Department of Neurology, St Vincent's Hospital, Sydney, Australia
| | - J Burrow
- Department of Neurology, Royal Darwin Hospital, Darwin, Northern Territory, Australia
| | - Y Nagree
- Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia, Perth, Australia.,Emergency Department, Fremantle Hospital, Fremantle, Western Australia, Australia
| | - P Leman
- Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia, Perth, Australia.,Emergency Department, Royal Perth Hospital, Perth, Australia
| | - D W Smith
- Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia, Perth, Australia
| | - K Read
- Department of Infectious Diseases, North Shore Hospital, Auckland, New Zealand, USA
| | - R Booy
- Discipline of Paediatrics and Child Health and Marie Bashir Institute for Emerging Infectious Diseases and Biosecurity, Sydney Medical School, University of Sydney, Sydney, Australia.,Department of Infectious Diseases and Microbiology, The Children's Hospital at Westmead, Sydney, Australia.,National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead, Sydney, Australia
| | - C A Jones
- Discipline of Paediatrics and Child Health and Marie Bashir Institute for Emerging Infectious Diseases and Biosecurity, Sydney Medical School, University of Sydney, Sydney, Australia.,Department of Infectious Diseases and Microbiology, The Children's Hospital at Westmead, Sydney, Australia
| | | | | | | | | |
Collapse
|
16
|
Bai HX, Zou Y, Lee AM, Lancaster E, Yang L. Diagnostic Value and Safety of Brain Biopsy in Patients With Cryptogenic Neurological Disease: A Systematic Review and Meta-analysis of 831 Cases. Neurosurgery 2016; 77:283-95; discussion 295. [PMID: 25856111 DOI: 10.1227/neu.0000000000000756] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND The role of brain biopsy in patients with cryptogenic neurological disease is uncertain. OBJECTIVE To determine the risks and benefits of diagnostic brain biopsy for nonneoplastic indications in immunocompetent patients. METHODS Appropriate studies were identified by searching electronic databases. RESULTS We screened 3645 abstracts and included 20 studies with a total of 831 patients. Indications for biopsy were: (1a) severe neurological disease of unknown etiology in adults (n = 7) and (1b) in children (n = 2); (2) suspected primary angiitis of the central nervous system (PACNS) (n = 3); (3) chronic meningitis of unknown cause (n = 3); (4) atypical dementia (n = 4); and (5) nonneoplastic disease (n = 1). Diagnostic success rates calculated for subgroups were 51.3% (34.5-68.1) for 1a, 53.8% (42.9-64.5) for 1b, 74.7% (64.0-84.1) for 2, 30.3% (17.2-45.4) for 3, and 60.8% (41.2-78.8) for 4. Clinical impact rates were 30.5% (13.6-50.6) for 1a (n = 6), 67.1% (42.8-87.3) for 1b (n = 2), 8.3% (2.3-20.0) for 3 (n = 1), and 14.2% (6.5-24.3) for 4 (n = 2). Lymphoma (n = 32) and Creutzfeldt-Jakob disease (n = 30) were the most common diagnoses on the final histopathology reports of positive brain biopsies in 1a. In 1b, encephalitis (n = 7), PACNS (n = 6), and demyelination (n = 6) were the most common. The odds ratio for achieving a diagnostic biopsy when there was a radiological target was 3.70 (P = .014, 95% confidence interval, 1.31-10.42). CONCLUSION Brain biopsy in cryptogenic neurological disease was associated with the highest diagnostic yield in patients with suspected PACNS. The greatest clinical impact was seen in children with cryptogenic neurological disease. The presence of a radiological target was associated with a higher diagnostic yield.
Collapse
Affiliation(s)
- Harrison Xiao Bai
- ‡Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; §Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia; ¶Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
| | | | | | | | | |
Collapse
|
17
|
Twilt M, Benseler SM. Central nervous system vasculitis in adults and children. HANDBOOK OF CLINICAL NEUROLOGY 2016; 133:283-300. [PMID: 27112683 DOI: 10.1016/b978-0-444-63432-0.00016-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Primary angiitis of the central nervous system (PACNS) is an inflammatory brain disease targeting the cerebral blood vessels, leading to a wide spectrum of signs and symptoms, including neurologic deficits, cognitive dysfunction, and psychiatric symptoms. The inflammation could be reversible if diagnosed and treated early. The diagnosis requires the careful consideration and rapid evaluation of systemic underlying conditions and disease mimics. The differential diagnosis is distinctly different for angiography-positive and -negative PACNS subtypes and differs depending on age, so there is childhood PACNS or adult PACNS. Distinct disease subtypes have been described, with characteristic disease course, neuroimaging findings, and histopathologic features. Novel and traditional biomarkers, including von Willebrand factor antigen and cytokine levels, can help diagnose, and define subtype and disease activity. Treatment of PACNS should be tailored to the disease subtypes and clinical symptoms. Beyond immunosuppression it should include medications to control symptoms in order to support and enhance the child's or adult's ability to actively participate in rehabilitation. The mortality of PACNS has decreased; studies determining the morbidity and its determinants are urgently needed.
Collapse
Affiliation(s)
- Marinka Twilt
- Division of Rheumatology, Department of Pediatrics, Aarhus University Hospital and Faculty of Medicine, University of Aarhus, Aarhus, Denmark; Division of Rheumatology, Department of Paediatrics, Alberta Children's Hospital, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada
| | - Susanne M Benseler
- Division of Rheumatology, Department of Paediatrics, Alberta Children's Hospital, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada.
| |
Collapse
|
18
|
|
19
|
Chabrier S, Darteyre S, Mazzola L, Stéphan JL. [Childhood cerebral vasculitis]. Arch Pediatr 2014; 21:884-93. [PMID: 24998326 DOI: 10.1016/j.arcped.2014.05.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2013] [Revised: 02/27/2014] [Accepted: 05/12/2014] [Indexed: 12/29/2022]
Abstract
Central nervous system vasculitides are defined as the invasion of the vascular wall by blood-borne inflammatory cells. In childhood, they may be classified according to their trigger event (infectious vs. non-infectious), their temporal course (time-limited vs. chronic), and the size of the affected vessel. Diseases apparently confined to the central nervous system are also distinguished from secondary forms, associated with infection or rheumatic or systemic inflammatory disorders. Large-vessel vasculitis, the most frequent form, causes stroke and presents with acute focal deficits. MR, or more seldom contrast angiography is required for the positive diagnosis, while the child's medical history conveys the etiological diagnosis. The clinical manifestations of small-vessel vasculitis include headaches, seizures, focal deficits, cognitive decline, and behavior changes that can occur insidiously over a few weeks or a few months. The diagnosis is based on the associated clinical and biological symptoms in secondary forms and on cerebromeningeal biopsy in primary forms. Secondary forms of vasculitides are treated according to the etiology. The injury of large basal arteries is often observed after infection, especially varicella, and is also called transient focal cerebral arteriopathy (TCA) or post-varicella arteriopathy (PVA). This focal, monophasic, and time-limited entity is highly specific of childhood. There are no arguments in the current literature supporting the hypothesis that an aggressive immunomodulatory treatment would be more effective, in terms of recurrence rate or functional outcome, than aspirin alone. In contrast, the diffuse, prolonged, and aggressive course of the rare primary vasculitis of the central nervous system requires a prolonged immunosuppressive treatment. The management of associated symptoms, treatment-related adverse effects, and sequelae is based on a multidisciplinary approach.
Collapse
Affiliation(s)
- S Chabrier
- Pôle Couple-Mère-Enfant, hôpital Bellevue, CHU de Saint-Etienne, 42055 Saint-Etienne cedex 2, France.
| | - S Darteyre
- Pôle Couple-Mère-Enfant, hôpital Bellevue, CHU de Saint-Etienne, 42055 Saint-Etienne cedex 2, France
| | - L Mazzola
- Pôle Couple-Mère-Enfant, hôpital Bellevue, CHU de Saint-Etienne, 42055 Saint-Etienne cedex 2, France
| | - J-L Stéphan
- Pôle Couple-Mère-Enfant, hôpital Bellevue, CHU de Saint-Etienne, 42055 Saint-Etienne cedex 2, France
| |
Collapse
|
20
|
Twilt M, Benseler SM. Childhood inflammatory brain diseases: pathogenesis, diagnosis and therapy. Rheumatology (Oxford) 2013; 53:1359-68. [PMID: 24324213 DOI: 10.1093/rheumatology/ket398] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Inflammatory brain diseases (IBrainDs) are a leading cause of devastating neurological deficits or neuropsychiatric syndromes in previously healthy children. The spectrum is expanding rapidly and new disease entities have been discovered in the last decade. IBrainD can occur as a primary disease or may occur secondary to an underlying cause. This review focuses on the clinical presentation, diagnostic features, pathology and histology characteristics and treatment of the primary childhood IBrainDs.
Collapse
Affiliation(s)
- Marinka Twilt
- Division of Rheumatology, Department of Paediatrics and Institute of Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.Division of Rheumatology, Department of Paediatrics and Institute of Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children, Toronto, ON, Canada
| | - Susanne M Benseler
- Division of Rheumatology, Department of Paediatrics and Institute of Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.Division of Rheumatology, Department of Paediatrics and Institute of Child Health Evaluative Sciences, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.
| |
Collapse
|
21
|
Moharir M, Shroff M, Benseler SM. Childhood central nervous system vasculitis. Neuroimaging Clin N Am 2013; 23:293-308. [PMID: 23608691 DOI: 10.1016/j.nic.2012.12.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Inflammatory brain diseases in childhood are underrecognized and lead to devastating yet potentially reversible deficits. New-onset neurologic or psychiatric deficits in previously healthy children mandate an evaluation for an underlying inflammatory brain disease. Distinct disease entities, such as central nervous system (CNS) vasculitis, are now being increasingly reported in children. Clinical symptoms, initial laboratory test, and neuroimaging studies help to differentiate between different causes; however, more invasive tests, such as lumbar puncture, conventional angiography, and/or brain biopsy, are usually necessary before the start of treatment. This article focuses on childhood CNS vasculitis.
Collapse
Affiliation(s)
- Mahendranath Moharir
- Division of Neurology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
| | | | | |
Collapse
|
22
|
Twilt M, Benseler SM. CNS vasculitis in children. Mult Scler Relat Disord 2013; 2:162-71. [DOI: 10.1016/j.msard.2012.11.002] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2012] [Revised: 10/27/2012] [Accepted: 11/19/2012] [Indexed: 01/20/2023]
|
23
|
Benseler S, Pohl D. Childhood central nervous system vasculitis. HANDBOOK OF CLINICAL NEUROLOGY 2013; 112:1065-78. [DOI: 10.1016/b978-0-444-52910-7.00024-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
|
24
|
Abstract
Central nervous system vasculitis is an increasingly recognized inflammatory brain disease causing devastating neurological deficits and psychiatric manifestations in previously healthy children. Primary central nervous system vasculitis represents an isolated inflammatory attack targeting the cerebral vessels. In contrast, in children with secondary central nervous system vasculitis, an underlying condition can be identified. The spectrum of childhood primary and secondary central nervous system vasculitis is rapidly expanding, as is the differential diagnosis including nonvasculitic inflammatory brain diseases and noninflammatory vasculopathies. Early recognition, rapid diagnostic evaluation, and initiation of treatment have led to improved morbidity and mortality. This review focuses on clinical, laboratory, and neuroimaging characteristics of the distinct subtypes of primary childhood central nervous system vasculitis, reports the etiology of secondary central nervous system vasculitis, provides an overview of the differential diagnosis, and reviews the current approaches in treatment.
Collapse
Affiliation(s)
- Peter Gowdie
- Department of Paediatrics, Division of Rheumatology, Child Health Evaluative Science, Research Institute, University of Toronto, Toronto, ON, Canada
| | | | | |
Collapse
|
25
|
Gilkes CE, Love S, Hardie RJ, Edwards RJ, Scolding NJ, Rice CM. Brain biopsy in benign neurological disease. J Neurol 2012; 259:995-1000. [DOI: 10.1007/s00415-012-6455-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2012] [Revised: 01/29/2012] [Accepted: 01/31/2012] [Indexed: 11/29/2022]
|
26
|
|
27
|
Rice CM, Gilkes CE, Teare E, Hardie RJ, Scolding NJ, Edwards RJ. Brain biopsy in cryptogenic neurological disease. Br J Neurosurg 2011; 25:614-20. [DOI: 10.3109/02688697.2010.551677] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
28
|
Abstract
PURPOSE OF REVIEW To review the current literature of childhood central nervous system vasculitis, and to discuss a tailored approach to diagnosis and treatment based on recent evidence. RECENT FINDINGS Primary angiitis of the central nervous system in children (cPACNS) is an increasingly recognized inflammatory brain disease with potentially devastating neurological consequences. The diagnostic approach should be tailored to the clinical presentation of the child with suspected cPACNS and should address the expanding spectrum of inflammatory and noninflammatory brain diseases with overlapping clinical features. New evidence has confirmed that elective brain biopsies in children have a higher diagnostic yield than in adults and improve our ability to diagnose angiography-negative cPACNS. Finally, observational studies have shown that early diagnosis and aggressive treatment lead to improved neurological outcomes and lower mortality rates in patients with cPACNS. SUMMARY This review summarizes the recent data on diagnosis, classification, treatment, and outcomes in cPACNS. Our improved understanding of cPACNS facilitates a tailored diagnostic approach that results in earlier diagnosis and initiation of therapy for this potentially reversible condition.
Collapse
|
29
|
Elbers J, Halliday W, Hawkins C, Hutchinson C, Benseler SM. Brain biopsy in children with primary small-vessel central nervous system vasculitis. Ann Neurol 2010; 68:602-10. [DOI: 10.1002/ana.22075] [Citation(s) in RCA: 91] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
30
|
|
31
|
Abstract
BACKGROUND Pediatric multiple sclerosis (MS), once considered a rare childhood illness, has been increasingly identified as an important childhood acquired neurologic disease requiring early recognition and intervention. SUMMARY We present a comprehensive review of the current terminology of acquired central nervous system demyelination in children, pertinent investigations, including magnetic resonance imaging and cerebrospinal fluid cerebrospinal fluid studies, and an approach to the differential diagnosis of pediatric onset MS. In addition, the recent studies exploring the epidemiology and pathobiology will be discussed. Finally, we present an algorithm for the treatment of episodes of demyelination along with chronic immunomodulatory therapeutic options in this patient population. CONCLUSIONS Although some similarities exist to adult onset MS, MS onset during childhood and adolescence presents unique diagnostic challenges and requires specialized multidisciplinary care for optimal management. National and international collaborative studies are underway to aid in the understanding of the early and ongoing pathogenesis of MS.
Collapse
|
32
|
Burns JD, Cadigan RO, Russell JA. Evaluation of brain biopsy in the diagnosis of severe neurologic disease of unknown etiology. Clin Neurol Neurosurg 2008; 111:235-9. [PMID: 19022558 DOI: 10.1016/j.clineuro.2008.10.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2008] [Revised: 10/02/2008] [Accepted: 10/07/2008] [Indexed: 10/21/2022]
Abstract
OBJECTIVE To determine the value of non-stereotactic brain biopsies in patients with severe neurologic disease of unknown etiology and indeterminate brain imaging. METHODS We reviewed 42 consecutive patients who underwent non-stereotactic brain biopsy at a single institution for evaluation of severe neurologic disease of unknown etiology. All patients had indeterminate or normal imaging results. Seventy-nine percent had been symptomatic for less than a year. Exclusion criteria were immunocompromise or a preoperative diagnosis of intracranial neoplasm. Diagnostic yield and surgical complication rate were calculated. We performed exploratory univariate analysis aimed at identifying clinical features possibly predictive of diagnostic biopsies. RESULTS A histologic diagnosis was achieved in 12 of 42 biopsies (29%). Three patients experienced minor transient complications from the procedure (7%). There were no permanent deficits or deaths. Treatment was altered based on biopsy result in five patients (12%). A more precise prognosis was obtained in eight patients (19%). In total, 11 different patients (26%) benefited from biopsy. Exploratory univariate analysis showed a possible inverse relationship between age and the likelihood of a diagnostic biopsy (OR=0.929; 95% CI=0.864-0.998). CONCLUSIONS Our data suggest that the value of non-stereotactic brain biopsy is sufficiently high and the morbidity sufficiently low to justify its use in carefully selected patients with severe neurologic disease that remains undiagnosed despite thorough less invasive evaluation.
Collapse
Affiliation(s)
- Joseph D Burns
- Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States.
| | | | | |
Collapse
|